申请人:ZERIA PHARMACEUTICAL CO., LTD.
公开号:EP1650189A1
公开(公告)日:2006-04-26
The invention provides a compound which exhibits satisfactory peroral absorbability and excellent antagonistic activity against NK-1 receptor or NK-2 receptor. The compound is a benzylamine derivative represented by formula (1) or a salt thereof.
本发明提供了一种化合物,它具有令人满意的口腔吸收性和对 NK-1 受体或 NK-2 受体的优异拮抗活性。该化合物是一种由式(1)表示的苄胺衍生物或其盐。